41O.F Outlook Therapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
0.3950 EUR
Close of Nov 11, 2026
0.1480 2.26
Market cap
EUR 96.2M
P/E
-
P/B
38.57x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is 41O.F undervalued?

Graham number

The Graham number of Outlook Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Outlook Therapeutics, Inc. fundamental analysis

No fundamental analysis for Outlook Therapeutics, Inc. yet.

Outlook Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Ce…

Full company profile